References
Brooklyn TN, Dunnill MG, Shetty A et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 55:505–509
Wallace HJ, Stacey MC (1998) Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. J Invest Dermatol 110:292–296
Teich N, Klugmann T (2014) Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis 8:85–86
Streit M, Beleznay Z, Braathen LR (2006) Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J 3:171–179
Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M (2014) Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis 20:213–227
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teich, N. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn’s disease. Tech Coloproctol 18, 965–966 (2014). https://doi.org/10.1007/s10151-014-1192-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10151-014-1192-2